Proprietary CNS pipeline
Evotec's proprietary projects specialize in finding new treatments for diseases of the Central Nervous System (CNS). The focus of research is on major CNS related conditions, including sleep disorders, Alzheimer's disease, pain management and smoking cessation - fast growing therapeutic areas with large unmet medical needs. Evotec has a diverse product pipeline with candidates at various stages of development. The Company's most advanced product candidate, which has recently completed Phase II clinical trials with excellent results, is EVT 201, a partial positive allosteric modulator of the GABAA receptor complex for the treatment of insomnia. Through selective in-licensing and the use of its platform for internal discovery efforts, Evotec intends to further develop and expand its preclinical and clinical CNS pipeline for partnering.
Research collaborations
In research collaborations, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide by providing high quality, innovative and integrated solutions from drug target to clinic through an unmatched range of capabilities, including assay development, high-throughput and high-content screening, fragment-based drug discovery and medicinal chemistry. Applying its proven expertise in close collaboration with customers, Evotec is committed to delivering the highest levels of research and can quote outstanding references with the names of the world's leading pharmaceutical and biotechnology companies appearing among its many partners. To fully exploit the potential of its capabilities, Evotec increasingly complements its traditional fee-for-service business with higher value, results-driven projects in core areas by sharing in the customer's risk and success through significant milestone payments and royalties.
Evotec is a high performance organization that manages for innovation and efficiency across all areas. We aim to recruit, train, motivate and retain premier talent and to support our partners through the partnering of preclinical and clinical assets as well as results-orientated, highly collaborative relationships, creating innovative solutions using outstanding capabilities and thought leadership.